This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tolerance of Cereals for Atopic Children

This study has been terminated.
(difficult to enrol and as a pilot study sample size was not powered anyway)
Information provided by (Responsible Party):
Nestlé Identifier:
First received: December 8, 2009
Last updated: June 26, 2012
Last verified: June 2012
In this study, non allergenic cereals will be tested in infants with atopic symptoms. The test will be performed in a hospital.

Condition Intervention
Allergy Other: commercialized complete cereals Other: commercialized complete cereals with additional ingredient

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of Tolerance of Cereals in Infants With Atopic Symptoms

Further study details as provided by Nestlé:

Primary Outcome Measures:
  • Documentation of atopic symptoms and clinical examination for presence or absence of some objective and subjective symptoms with evaluation of severity (SCORAD) if necessary [ Time Frame: 48 hours ]

Secondary Outcome Measures:
  • Morbidity will be assessed by the frequency of adverse events [ Time Frame: 48 hours ]

Enrollment: 45
Study Start Date: February 2010
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: complete non allergenic cereals
existing commercialized product
Other: commercialized complete cereals
complete cereals suitable for the weaning period
Experimental: complete non allergenic cereals plus
commercialised product with the addition of a novel ingredient
Other: commercialized complete cereals with additional ingredient
complete cereals suitable for weaning period

Detailed Description:

In the majority of food allergy cases, an exclusion diet results in regression of clinical symptoms but this diet may not be nutritionally complete. To feed a baby who has a food allergy, we want a food with low allergenic ingredients.

For this reason, a complete cereal has been specially developed and formulated for the weaning period of infants and young children suffering from milk, soy or wheat protein allergy or hypersensitivity due to celiac disease.

It allows a smooth transition into and through the weaning period. The ingredients of this product are all from vegetable sources and it is therefore suitable for a vegetarian diet. It has been commercialised for many years and has proved to be completely safe, however so far no study has been specifically designed and powered to assess tolerance of this product in infants with atopic symptoms.

In this study we are testing the tolerance (symptoms stability) of non allergenic cereals during an open allergenic test in infants with atopic symptoms and/or positive Skin Prick Test (SPT) or positive specific RAST-IgE or positive Patch Test. We are also testing the same product containing an additional ingredient with a potential effect in allergy management.

Such complete cereals is a very good option for allergic children in comparison to an exclusion diet that may not be nutritionally complete.


Ages Eligible for Study:   4 Months to 4 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Infant aged from 4 to 40 months at the time of enrolment
  • With atopic symptoms and/or positive Skin Prick Test (SPT) or positive specific RAST-IgE or positive Patch Test
  • Infants who received a specific elimination oligoallergenic diet from the study site for at least 5 days before the day of enrolment
  • Having obtained his/her signed legal representative's informed consent

Exclusion Criteria:

  • Infant on systemic drugs (e.g. antihistamines) according to half-life at time of enrolment
  • Congenital illness or malformation that may affect normal growth (especially immunodeficiency)
  • Infant whose parents / caregivers cannot be expected to comply with treatment.
  • Infant currently participating in another interventional clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01029184

Kinderarzt-Allergologie-Sportmedizin Fachklinik Gaißach
Gaißach bei Bad Tölz, Germany, 83674
Sponsors and Collaborators
  More Information

Responsible Party: Nestlé Identifier: NCT01029184     History of Changes
Other Study ID Numbers: 07.47.INF
Study First Received: December 8, 2009
Last Updated: June 26, 2012

Keywords provided by Nestlé:
open allergenic test processed this record on August 18, 2017